Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Richard Vile"'
Autor:
Mason J. Webb, Thanich Sangsuwannukul, Jacob van Vloten, Laura Evgin, Benjamin Kendall, Jason Tonne, Jill Thompson, Muriel Metko, Madelyn Moore, Maria P. Chiriboga Yerovi, Michael Olin, Antonella Borgatti, Mark McNiven, Satdarshan P. S. Monga, Mitesh J. Borad, Alan Melcher, Lewis R. Roberts, Richard Vile
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Although patients benefit from immune checkpoint inhibition (ICI) therapy in a broad variety of tumors, resistance may arise from immune suppressive tumor microenvironments (TME), which is particularly true of hepatocellular carcinoma (HCC).
Externí odkaz:
https://doaj.org/article/3cf0fc38fa494b069051f0ff5e7872c6
Autor:
Jack Swanson, Jason Tonne, Thanich Sangsuwannukul, Jill Thompson, Benjamin Kendall, Olivia Liseth, Muriel Metko, Richard Vile
Publikováno v:
Molecular Therapy: Oncology, Vol 32, Iss 4, Pp 200873- (2024)
Chimeric antigen receptor (CAR) T cells are a clinically approved therapy for blood cancers. To produce clinical-grade CAR T cells, a retroviral or lentiviral vector is used to deliver the CAR and associated genes to patient T cells. Apolipoprotein B
Externí odkaz:
https://doaj.org/article/d31cc90c2f2343a696e8941748484f1a
Autor:
Mason J. Webb, Timothy Kottke, Benjamin L. Kendall, Jack Swanson, Chisom Uzendu, Jason Tonne, Jill Thompson, Muriel Metko, Madelyn Moore, Mitesh Borad, Lewis Roberts, Rosa M. Diaz, Michael Olin, Antonella Borgatti, Richard Vile
Publikováno v:
Molecular Therapy: Oncolytics, Vol 29, Iss , Pp 129-142 (2023)
In multiple models of oncolytic virotherapy, it is common to see an early anti-tumor response followed by recurrence. We have previously shown that frontline treatment with oncolytic VSV-IFN-β induces APOBEC proteins, promoting the selection of spec
Externí odkaz:
https://doaj.org/article/7ab80cb6ce704e9f9a41cf0126c80a1b
Autor:
Nicola E. Annels, Guy R. Simpson, Mick Denyer, Mehreen Arif, Matt Coffey, Alan Melcher, Kevin Harrington, Richard Vile, Hardev Pandha
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 434-446 (2021)
Prostate cancers are considered “cold” tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells. This non-inflamed phenotype is likely responsible for the lack
Externí odkaz:
https://doaj.org/article/1fcecfe43cb14392b18d5ef88fd32378
Autor:
Victoria Jennings, Kevin Harrington, Hardev Pandha, Alan Melcher, Adel Samson, Fiona Errington-Mais, Victoria Roulstone, Eva Crespo-Rodriguez, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Martin McLaughlin, Malin Pedersen, Richard Vile, Joan Kyula, Jehanne Hassan, Lizzie Appleton, Charleen ML Chan Wah Hak, Gabby Baker, Edward Armstrong, Matthew Chiu, Masahiro Ono
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to i
Externí odkaz:
https://doaj.org/article/316204113b0e4019ac28423a26ae7cf2
Autor:
Laura Evgin, Amanda L. Huff, Phonphimon Wongthida, Jill Thompson, Tim Kottke, Jason Tonne, Matthew Schuelke, Katayoun Ayasoufi, Christopher B. Driscoll, Kevin G. Shim, Pierce Reynolds, Dileep D. Monie, Aaron J. Johnson, Matt Coffey, Sarah L. Young, Gary Archer, John Sampson, Jose Pulido, Luis Sanchez Perez, Richard Vile
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Oncolytic viruses promote an inflammatory response and elicit anti-tumor immunity. Here the authors show, unexpectedly, that the oncolytic virus, VSVIFNβ, induces type I interferon responses that, when combined with chimeric antigen receptor (CAR) T
Externí odkaz:
https://doaj.org/article/5178c922fdee4c4491424f98809482c4
Autor:
Martin McLaughlin, Malin Pedersen, Victoria Roulstone, Katharina F. Bergerhoff, Henry G. Smith, Harriet Whittock, Joan N. Kyula, Magnus T. Dillon, Hardev S. Pandha, Richard Vile, Alan A. Melcher, Kevin J. Harrington
Publikováno v:
Molecular Therapy: Oncolytics, Vol 16, Iss , Pp 238-249 (2020)
Reovirus type 3 Dearing (reovirus) is a tumor-selective oncolytic virus currently under evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head and neck squamous cell cancer can be enhanced by targeting the un
Externí odkaz:
https://doaj.org/article/ea1817def2d74912aacb316306d0be16
Autor:
Kevin Harrington, Hardev Pandha, Alan Melcher, David Mansfield, Johann De Bono, Victoria Roulstone, Christine White, James Spicer, Richard Vile, Sophia N Karagiannis, Robert J Harris, Katie Twigger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to improve the therapeutic potential
Externí odkaz:
https://doaj.org/article/49c464594a2942fdbb0141fdfc412103
Autor:
Nicola E. Annels, Mehreen Arif, Guy R. Simpson, Mick Denyer, Carla Moller-Levet, David Mansfield, Rachel Butler, Darren Shafren, Gough Au, Margaret Knowles, Kevin Harrington, Richard Vile, Alan Melcher, Hardev Pandha
Publikováno v:
Molecular Therapy: Oncolytics, Vol 9, Iss , Pp 1-12 (2018)
As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhe
Externí odkaz:
https://doaj.org/article/547e325fd60c43019bb01a1537f873cb
Autor:
Julia V. Cockle, Anke Brüning-Richardson, Karen J. Scott, Jill Thompson, Timothy Kottke, Ewan Morrison, Azam Ismail, Angel M. Carcaboso, Ailsa Rose, Peter Selby, Joe Conner, Susan Picton, Susan Short, Richard Vile, Alan Melcher, Elizabeth Ilett
Publikováno v:
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 75-86 (2017)
Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) are invasive tumors with poor survival. Oncolytic virotherapy, initially devised as a direct cytotoxic treatment, is now also known to act via immune-mediated mechanisms.
Externí odkaz:
https://doaj.org/article/6daa5830e2af4d63a0235f4c00e305f7